Intellia Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (33)

Latest Posts

About This Stock More About This Stock
Winners Of Q1 Earnings: 5 Best ETF Charts
Article By: Sweta Killa
Sunday, May 27, 2018 4:01 PM EST
several equity ETFs have impressed with their performances and generated handsome returns over the trailing one month even after being hit by the trade worries and geopolitical tensions. Here are five ETFs that buoyed up on robust earnings results.
In this article: PTH, SPY, PSCE, GAMR, ARKK, ILMN, SSYS, TSLA, EDIT, NTLA, MKSI, FTXL
Read
Is Ardelyx Inc A Good Stock To Buy Right Now?
Article By: Insider Monkey
Saturday, December 10, 2016 5:20 PM EST
ARDX was in 13 hedge funds' portfolios at the end of September up from nine the previous quarter. The level and the change in hedge fund popularity aren't the only variables you need to analyze to decipher hedge funds' perspectives.
In this article: NPK, TCBK, ARDX, NTLA
Read
IPO Quiet Period Expiration For Intellia Therapeutics Offers A Buying Opportunity
Article By: Don Dion
Tuesday, May 24, 2016 1:03 PM EST
The stock has grown in its early market performance.
In this article: NTLA
Read
Intellia Jumps On CRISPR IPO Bandwagon
Article By: IPO Candy
Thursday, May 5, 2016 4:10 PM EST
Editas (EDIT) proved that investor interest in its area is high. Intellia is another high-quality player. These are really call options “worth” about $1B each right now.
In this article: NTLA, EDIT
Read
Intellia Therapeutics IPO: Regulatory Scrutiny Keeps Us Cautious
Article By: Don Dion
Tuesday, May 3, 2016 5:13 AM EST
Intellia Therapeutics expects to price its Nasdaq IPO this Thurs., 5.5; lead underwriters for the deal are Credit Suisse, Jeffries, and Leerink Partners. We believe NTLA is an uncertain bet at present and suggest investors consider holding off.
In this article: NTLA
Read

PARTNER HEADLINES

Latest Tweets for $NTLA

No tweets yet!